Literature DB >> 15729334

Structure of an unliganded simian immunodeficiency virus gp120 core.

Bing Chen1, Erik M Vogan, Haiyun Gong, John J Skehel, Don C Wiley, Stephen C Harrison.   

Abstract

Envelope glycoproteins of human and simian immunodeficiency virus (HIV and SIV) undergo a series of conformational changes when they interact with receptor (CD4) and co-receptor on the surface of a potential host cell, leading ultimately to fusion of viral and cellular membranes. Structures of fragments of gp120 and gp41 from the envelope protein are known, in conformations corresponding to their post-attachment and postfusion states, respectively. We report the crystal structure, at 4 A resolution, of a fully glycosylated SIV gp120 core, in a conformation representing its prefusion state, before interaction with CD4. Parts of the protein have a markedly different organization than they do in the CD4-bound state. Comparison of the unliganded and CD4-bound structures leads to a model for events that accompany receptor engagement of an envelope glycoprotein trimer. The two conformations of gp120 also present distinct antigenic surfaces. We identify the binding site for a compound that inhibits viral entry.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15729334     DOI: 10.1038/nature03327

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  294 in total

1.  Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography.

Authors:  Tommi A White; Alberto Bartesaghi; Mario J Borgnia; M Jason V de la Cruz; Rachna Nandwani; James A Hoxie; Julian W Bess; Jeffrey D Lifson; Jacqueline L S Milne; Sriram Subramaniam
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome.

Authors:  Srinika Ranasinghe; Michael Flanders; Sam Cutler; Damien Z Soghoian; Musie Ghebremichael; Isaiah Davis; Madelene Lindqvist; Florencia Pereyra; Bruce D Walker; David Heckerman; Hendrik Streeck
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

Review 3.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

4.  Role for the terminal clasp of HIV-1 gp41 glycoprotein in the initiation of membrane fusion.

Authors:  Chan-Sien Lay; Louise E Ludlow; David Stapleton; Anna K Bellamy-McIntyre; Paul A Ramsland; Heidi E Drummer; Pantelis Poumbourios
Journal:  J Biol Chem       Date:  2011-10-05       Impact factor: 5.157

5.  Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120.

Authors:  Miklos Guttman; Maria Kahn; Natalie K Garcia; Shiu-Lok Hu; Kelly K Lee
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

6.  HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

Authors:  James M Kovacs; Joseph P Nkolola; Hanqin Peng; Ann Cheung; James Perry; Caroline A Miller; Michael S Seaman; Dan H Barouch; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-05       Impact factor: 11.205

7.  HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.

Authors:  Jennifer M Pfaff; Craig B Wilen; Jessamina E Harrison; James F Demarest; Benhur Lee; Robert W Doms; John C Tilton
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

8.  Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure.

Authors:  Shang-Rung Wu; Robin Löving; Birgitta Lindqvist; Hans Hebert; Philip J B Koeck; Mathilda Sjöberg; Henrik Garoff
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

9.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Authors:  Nicos Karasavvas; Erik Billings; Mangala Rao; Constance Williams; Susan Zolla-Pazner; Robert T Bailer; Richard A Koup; Sirinan Madnote; Duangnapa Arworn; Xiaoying Shen; Georgia D Tomaras; Jeffrey R Currier; Mike Jiang; Craig Magaret; Charla Andrews; Raphael Gottardo; Peter Gilbert; Timothy J Cardozo; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Robert Paris; Kelli Greene; Hongmei Gao; Sanjay Gurunathan; Jim Tartaglia; Faruk Sinangil; Bette T Korber; David C Montefiori; John R Mascola; Merlin L Robb; Barton F Haynes; Viseth Ngauy; Nelson L Michael; Jerome H Kim; Mark S de Souza
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

10.  Antigenic properties of the HIV envelope on virions in solution.

Authors:  Krishanu Ray; Meron Mengistu; Lei Yu; George K Lewis; Joseph R Lakowicz; Anthony L DeVico
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.